Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review

被引：20

作者：

Buzon-Martin, Luis ^{[1
,2
]}

Zollner-Schwetz, Ines ^{[3
]}

Tobudic, Selma ^{[4
]}

Cercenado, Emilia ^{[5
,6
,7
]}

Lora-Tamayo, Jaime ^{[2
,8
,9
]}

机构：

[1] Hosp Univ Burgos, Dept Internal Med, Infect Dis Div, Burgos 09006, Spain

[2] Spanish Soc Infect Dis & Clin Microbiol GEIO SEIM, Bone & Joint Infect Study Grp, Madrid 28003, Spain

[3] Med Univ Graz, Dept Internal Med, Sect Infect Dis & Trop Med, A-8036 Graz, Austria

[4] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, A-1090 Vienna, Austria

[5] Hosp Gen Univ Gregorio Maranon, Serv Microbiol & Enfermedades Infecciosas, Madrid 28007, Spain

[6] CIBER Enfermedades Resp CIBERES, CB06-06-0058, Madrid 28029, Spain

[7] Univ Complutense Madrid, Sch Med, Med Dept, Madrid 28040, Spain

[8] Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre I 12, Dept Internal Med, Madrid 28041, Spain

[9] Red Espanola Invest Patol Infecciosa REIPI, Madrid 28029, Spain

来源：

ANTIBIOTICS-BASEL | 2021年 / 10卷 / 06期

关键词：

dalbavancin; prosthetic joint infection; gram-positive; IN-VITRO ACTIVITY; RESISTANT STAPHYLOCOCCUS-AUREUS; ONCE-WEEKLY DALBAVANCIN; UNITED-STATES; PHARMACOKINETICS; SKIN; SURVEILLANCE; BIOFILMS; SPECTRUM; THERAPY;

D O I：

10.3390/antibiotics10060656

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.

引用

页数：12

共 58 条

[21] Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue [J].

Dunne, Michael W. ;

Puttagunta, Sailaja ;

Sprenger, Craig R. ;

Rubino, Chris ;

Van Wart, Scott ;

Baldassarre, James .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) :1849-1855

[22] In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections [J].

Fernandez, Javier ;

Greenwood-Quaintance, Kerryl E. ;

Patel, Robin .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 85 (04) :449-451

[23] Effect of antibiotics on biofilm inhibition and induction measured by real-time cell analysis [J].

Ferrer, M. D. ;

Rodriguez, J. C. ;

Alvarez, L. ;

Artacho, A. ;

Royo, G. ;

Mira, A. .

JOURNAL OF APPLIED MICROBIOLOGY, 2017, 122 (03) :640-650

[24] Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms [J].

Fritsche, Thomas R. ;

Rennie, Robert P. ;

Goldstein, Beth P. ;

Jones, Ronald N. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (08) :2988-2990

[25] In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, Y ;

Tyrrell, K ;

Fernandez, HT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1968-1971

[26] In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections [J].

Goldstein, Ellie J. C. ;

Citron, Diane M. ;

Warren, Yumi A. ;

Tyrrell, Kerin L. ;

Merriam, C. Vreni ;

Fernandez, Helen T. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2875-2879

[27] Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System [J].

Gonzalez, Julia ;

Andrade, Diana Carolina ;

Niu, Jianli .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) :E1436-E1442

[28] DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci [J].

Hidalgo-Tenorio, Carmen ;

Vinuesa, David ;

Plata, Antonio ;

Davila, Pilar Martin ;

Iftimie, Simona ;

Sequera, Sergio ;

Loeches, Belen ;

Eduardo Lopez-Cortes, Luis ;

Carmen Farinas, Mari ;

Fernandez-Roldan, Concepcion ;

Javier-Martinez, Rosario ;

Munoz, Patricia ;

del Mar Arenas-Miras, Maria ;

Javier Martinez-Marcos, Francisco ;

Maria Miro, Jose ;

Herrero, Carmen ;

Bereciartua, Elena ;

De Jesus, Samantha E. ;

Pasquau, Juan .

ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2019, 18 (01)

[29] Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases [J].

Hitzenbichler, Florian ;

Mohr, Arno ;

Camboni, Daniele ;

Simon, Michaela ;

Salzberger, Bernd ;

Hanses, Frank .

INFECTION, 2021, 49 (01) :181-186

[30] Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections [J].

Jauregui, LE ;

Babazadeh, S ;

Seltzer, E ;

Goldberg, L ;

Krievins, D ;

Frederick, M ;

Krause, D ;

Satilovs, I ;

Endzinas, Z ;

Breaux, J ;

O'Riordan, W .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (10) :1407-1415

← 1 2 3 4 5 6 →